BIT Capital GmbH Raises Stock Holdings in Compass Pathways PLC Sponsored ADR $CMPS

Key Points

• BIT Capital GmbH boosted its position in Compass Pathways by 2,963.4% in Q4, buying an additional 279,386 shares to hold 288,814 shares (about 0.30% of the company) valued at $1.993 million per its latest 13F filing.
• Despite a consensus analyst rating of "Moderate Buy" with a $20.70 price target, Compass reported a quarterly EPS miss (−$1.00 vs. −$0.41 expected) and trades around $8.44 with a market cap of about $1.09 billion and a 52‑week range of $2.25–$10.21.

BIT Capital GmbH increased its position in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) by 2,963.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 288,814 shares of the company's stock after buying an additional 279,386 shares during the quarter. BIT Capital GmbH owned 0.30% of Compass Pathways worth $1,993,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in CMPS. CWM LLC boosted its holdings in shares of Compass Pathways by 19.2% during the 3rd quarter. CWM LLC now owns 15,650 shares of the company's stock valued at $90,000 after buying an additional 2,525 shares in the last quarter. Raymond James Financial Inc. boosted its holdings in shares of Compass Pathways by 82.7% during the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company's stock valued at $79,000 after buying an additional 6,228 shares in the last quarter. Advisory Services Network LLC bought a new stake in shares of Compass Pathways during the 3rd quarter valued at $41,000. Intellectus Partners LLC boosted its holdings in shares of Compass Pathways by 22.0% during the 4th quarter. Intellectus Partners LLC now owns 61,000 shares of the company's stock valued at $421,000 after buying an additional 11,000 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Compass Pathways by 65.0% during the 3rd quarter. Bank of America Corp DE now owns 30,498 shares of the company's stock valued at $175,000 after buying an additional 12,017 shares in the last quarter. Institutional investors own 46.19% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CMPS. Weiss Ratings reiterated a "sell (d-)" rating on shares of Compass Pathways in a research note on Monday, April 20th. Morgan Stanley dropped their price target on shares of Compass Pathways from $18.00 to $16.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 25th. Canaccord Genuity Group dropped their price target on shares of Compass Pathways from $20.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, March 26th. B. Riley Financial began coverage on shares of Compass Pathways in a research note on Friday, April 24th. They issued a "buy" rating and a $17.00 price target on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of Compass Pathways in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Compass Pathways presently has a consensus rating of "Moderate Buy" and a consensus price target of $20.70.

Compass Pathways Price Performance

NASDAQ CMPS opened at $8.44 on Wednesday. Compass Pathways PLC Sponsored ADR has a 52 week low of $2.25 and a 52 week high of $10.21. The firm has a market capitalization of $1.09 billion, a P/E ratio of -2.73 and a beta of 2.01. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 0.55. The company has a 50-day moving average price of $6.76 and a 200-day moving average price of $6.50.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings results on Tuesday, March 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.59). Equities research analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.83 earnings per share for the current year.

Compass Pathways Company Profile

Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.